OGT - Pioneers in hybridisation technology (original) (raw)
Welcome to our International website
This website is not intended for residents based in the USA or Canada
Choose from over one hundred high-quality DNA FISH probes for the detection of genetic aberrations found in cancer and inherited genetic diseases.
Featuring the new constitutional NGS platform for cytogenetic research, alongside a broad range of arrays for rare disease and cancer research.
Choose from preloaded NGS panels for haematological and solid tumour cancer research or we can help you create your own.
Try our handy FISH and NGS product tools
FISH chromosome search
Constitutional NGS chromosome search
Custom NGS cancer panel builder
Featured products
SureSeq Myeloid Fusion NGS Panel
Developed in partnership with myeloid cancer experts to the latest WHO guidance, the panel can identify novel fusion partners — providing more comprehensive and informative analyses than possible using PCR-driven methods. The figure (right) shows the consistent and confident detection of MECOM overexpression in [A] serial dilutions of HNT-34 cell line as well as [B] research and commercial samples, including positive and negative controls.
New...Del(5q) Plus Tri-Colour Deletion & CBFB Breakapart Probes
The triple colour design of the Del(5q) Plus Tri-Colour Deletion Probe facilitates the detection of 5q interstitial proximal and distal deletions, in addition to monosomy 5 in AML and MDS analysis. The CytoCell CBFB Breakapart Probe, with its dual colour, dual fusion probe design, detects rearrangements in the 16q22 region and overcomes limitations associated with the proximity of signals on chromosome 16 during interphase FISH for AML detection.
CytoSure Comprehensive FH Panel
Familial Hypercholesterolaemia (FH) is a genetic condition which results in a high cholesterol level and subsequently leads to a higher risk of early heart disease. OGT is offering an optimised NGS panel which has selected the most relevant genes and SNPs implicated in FH, for your research needs. The figure (left) shows a double deletion on the LDLR gene, as visualised by Interpret software.
What binds us, makes us.
We believe that collaboration is key to improving patient lives. By sharing our knowledge and expertise, we ensure that we move forward with our customers, bound by a collective commitment to unlocking the future of genetic clinical care. See our story.
